Related Experiment Video
Updated: Sep 4, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
[CAMK2a Regulates Paclitaxel Resistance in Oral Squamous Cell Carcinoma Cells by Activating the ERK Signaling
Junfeng Wang1, Hongli Chen1, Jiao Chen1
1( 610041)State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
Objective:
To investigate the molecular mechanisms by which calcium signaling pathways regulate the paclitaxel resistance and the survival of oral squamous cell carcinoma (OSCC) cells.
Methods:
A paclitaxel-resistant OSCC cell model was established through continuous low-dose paclitaxel induction with dose escalation. The stability of the paclitaxel-resistant model was assessed using the Cell Counting Kit-8 (CCK-8) and imaging flow cytometry. RNA sequencing (RNA-seq) was performed to analyze differentially expressed genes and functional enrichment. Quantitative real-time PCR (qPCR) was conducted to analyze the differential expression of the CAMK2a gene. Protein expression levels were assessed by Western blot (WB). CAMK2a expression was inhibited using KN93 and CAMK2a small interfering RNA (siRNA).
Results:
A paclitaxel-resistant OSCC cell model was successfully established. Gene Ontology (GO) enrichment analysis of the sequencing data revealed differences in the calcium signaling pathways in resistant cells. The expression of multiple genes of the CAMK2 family was upregulated, and CAMK2a expression increased by 12% (P < 0.05). After inhibiting CAMK2a by treatment with KN93, an inhibitor, and CAMK2a siRNA-mediated gene knockdown, the proliferative capacity of paclitaxel-resistant cells decreased by 35% (P < 0.0001). Furthermore, the expression levels of phosphorylated Erk1/2 (p-Erk1/2) and its downstream signaling molecules also decreased following CAMK2a inhibition.
Conclusion:
CAMK2a regulates drug resistance and the proliferative capacity of paclitaxel-resistant cells by activating the MAPK-Erk1/2 pathway and represents a potential new therapeutic target for clinical treatment of drug-resistant patients.
Related Concept Videos
MAPK Signaling Cascades
PI3K/mTOR/AKT Signaling Pathway
Inhibition of Cdk Activity
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Mitogens and the Cell Cycle